Flagship-backed Axcella seeking NASDAQ IPO

With its lead program headed for its first post-IND clinical study, Axcella proposed to raise up to $86.3 million in an IPO on NASDAQ.

Axcella Health Inc. (Cambridge, Mass.) is developing a pipeline of endogenous metabolic modulators, including five oral mixtures of multiple amino acids designed to modulate liver, muscle or blood metabolism. It has begun testing the programs in non-IND, IRB-approved clinical studies...